These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 32389444)

  • 1. Reply to Nirmish Singla and Vitaly Margulis's Letter to the Editor re: Geraldine Pignot, Antoine Thiery-Vuillemin, Jochen Walz, et al. Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.018. The Next Surgical Frontier in Kidney Cancer: Nephrectomy After Immune Checkpoint Inhibition: Nephrectomy After Immunotherapy: The Duration of Treatment Exposure is Probably Decisive.
    Pignot G; Thiery-Vuillemin A; Walz J; Bigot P; Bensalah K; Gravis G; Barthélémy P
    Eur Urol; 2020 Aug; 78(2):e81-e82. PubMed ID: 32389444
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Geraldine Pignot, Antoine Thiery-Vuillemin, Jochen Walz, et al. Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.018: The Next Surgical Frontier in Kidney Cancer: Nephrectomy After Immune Checkpoint Inhibition.
    Singla N; Margulis V
    Eur Urol; 2020 Aug; 78(2):e79-e80. PubMed ID: 32362497
    [No Abstract]   [Full Text] [Related]  

  • 3. Reply to Johanna Noel, Olivier Huillard, and Francois Goldwasser's Letter to the Editor re: Keiichiro Mori, Mohammad Abufaraj, Hadi Mostafaei, et al. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.10.006. Clinical Activity of Immune Checkpoint Inhibitors: Is the Host the Answer?
    Mori K; Schmidinger M; Egawa S; Gust KM; Shariat SF
    Eur Urol; 2021 Apr; 79(4):e113-e114. PubMed ID: 33487477
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: Bimal Bhindi, Jeffrey Graham, J. Connor Wells, et al. Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.04.038: Cytoreductive Nephrectomy: To Whom and When?
    Mollica V; Rizzo A; Massari F
    Eur Urol Oncol; 2020 Aug; 3(4):559-560. PubMed ID: 32553708
    [No Abstract]   [Full Text] [Related]  

  • 5. Re: Keiichiro Mori, Mohammad Abufaraj, Hadi Mostafaei, et al. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.10.006: Clinical Activity of Immune Checkpoint Inhibitors: Is the Host the Answer?
    Noel J; Huillard O; Goldwasser F
    Eur Urol; 2021 Apr; 79(4):e112. PubMed ID: 33518379
    [No Abstract]   [Full Text] [Related]  

  • 6. Reply to Hiten D. Patel and Mohamad E. Allaf's letter to the editor re: Maxine Sun, Andreas Becker, Zhe Tian, et al. Management of localized kidney cancer: calculating cancer-specific mortality and competing risks of death for surgery and nonsurgical management. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2013.03.034.
    Sun M; Karakiewicz PI; Trinh QD
    Eur Urol; 2013 Nov; 64(5):e107-8. PubMed ID: 23910940
    [No Abstract]   [Full Text] [Related]  

  • 7. Reply to Mengda Zhang and Long Wang's Letter to the Editor re: Francesco Porpiglia, Enrico Checcucci, Daniele Amparore, et al. Three-dimensional Augmented Reality Robot-assisted Partial Nephrectomy in Case of Complex Tumours (PADUA ≥ 10): A New Intraoperative Tool Overcoming the Ultrasound Guidance. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.11.024.
    Amparore D; Checcucci E; Fiori C; Porpiglia F
    Eur Urol; 2020 Jun; 77(6):e163-e164. PubMed ID: 32279902
    [No Abstract]   [Full Text] [Related]  

  • 8. Re: Kosuke Takemura, Matthew S. Ernst, Vishal Navani, et al. Characterization of Patients with Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.10.002.
    Ishiyama Y; Urabe F
    Eur Urol Oncol; 2024 Jun; 7(3):642-643. PubMed ID: 38238222
    [No Abstract]   [Full Text] [Related]  

  • 9. Re: Longbin Xiong, Jane K. Nguyen, Yulu Peng, et al. What Happens to the Preserved Renal Parenchyma After Clamped Partial Nephrectomy? Eur Urol. 2022;81:492-500. https://doi.org/10.1016/j.eururo.2021.12.036.
    Ren S; Zhong S; Fan S; Li X; Zhou F; Wang D
    Eur Urol; 2022 Aug; 82(2):e49. PubMed ID: 35570147
    [No Abstract]   [Full Text] [Related]  

  • 10. Reply to Xiaoshuai Gao, Guo Chen, and Xin Wei's Letter to the Editor re: Keiichiro Mori, Mohammad Abufaraj, Hadi Mostafaei, et al. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. Eur Urol 2021;79:783-92.
    Mori K; Schmidinger M; Egawa S; Gust KM; Shariat SF
    Eur Urol; 2021 Dec; 80(6):e145-e146. PubMed ID: 34579998
    [No Abstract]   [Full Text] [Related]  

  • 11. Re: Ziad Bakouny, Talal El Zarif, Shaan Dudani, et al. Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol 2023;83:145-51.
    Li J; Chen B; Cao D
    Eur Urol; 2023 Sep; 84(3):e75. PubMed ID: 37270390
    [No Abstract]   [Full Text] [Related]  

  • 12. Reply to Daniel D. Shapiro, Jose A. Karam, Viraj A. Master, et al.'s Letter to the Editor re: Wesley Yip, Alireza Ghoreifi, Thomas Gerald, et al. Perioperative Complications and Oncologic Outcomes of Nephrectomy Following Immune Checkpoint Inhibitor Therapy: A Multicenter Collaborative Study. Eur Urol Oncol. Eur Urol. Onc. 2023;604-610.
    Yip W; Ghoreifi A; Djaladat H
    Eur Urol Oncol; 2023 Dec; 6(6):637. PubMed ID: 37316397
    [No Abstract]   [Full Text] [Related]  

  • 13. Reply to Alireza Ghoreifi and Hooman Djaladat's Letter to the Editor re: Daniel D. Shapiro, Jose A. Karam, Logan Zemp, et al. Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Therapy Is Safe and Facilitates Treatment-free Intervals. Eur Urol Open Sci 2023;50:43-6.
    Shapiro DD; Karam JA; Master VA; Zemp LW; Sexton WJ; Matin SF; Spiess PE; Jason Abel E
    Eur Urol; 2023 Aug; 84(2):e55-e56. PubMed ID: 37149462
    [No Abstract]   [Full Text] [Related]  

  • 14. Reply to Binghao Zhao, Ruidong Zhang, and Jiaming Wu's Letter to the Editor re: Ana Cavillon, Damien Pouessel, Nadine Houédé, et al. Assessing Long-term Treatment Benefits Using Complementary Statistical Approaches: An In Silico Analysis of the Phase III Keynote-045 and Checkmate-214 Immune Checkpoint Inhibitor Trials. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.02.011.
    Cavillon A; Porcher R; Filleron T
    Eur Urol; 2023 Jul; 84(1):e22-e23. PubMed ID: 37120335
    [No Abstract]   [Full Text] [Related]  

  • 15. Re: Maxine Sun, Andreas Becker, Zhe Tian, et al. Management of localized kidney cancer: calculating cancer-specific mortality and competing risks of death for surgery and nonsurgical management. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2013.03.034.
    Patel HD; Allaf ME
    Eur Urol; 2013 Nov; 64(5):e105-6. PubMed ID: 23910939
    [No Abstract]   [Full Text] [Related]  

  • 16. Reply to Nikolaos Grivas, Sanchia Goonewardene, Wouter Everaerts, Nikolaos Kalampokis's Letter to the Editor re: Andrea Mari, Riccardo Tellini, Francesco Porpiglia, et al. Perioperative and Mid-term Oncological and Functional Outcomes After Partial Nephrectomy for Complex (PADUA Score ≥10) Renal Tumors: A Prospective Multicenter Observational Study (the RECORD2, Project). Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2020.07.004.
    Mari A; Tellini R; Ficarra V; Carini M; Minervini A;
    Eur Urol Focus; 2021 Sep; 7(5):1212-1213. PubMed ID: 33384273
    [No Abstract]   [Full Text] [Related]  

  • 17. Re: Daniel D. Shapiro, Jose A. Karam, Logan Zemp, et al. Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Therapy Is Safe and Facilitates Treatment-free Intervals. Eur Urol Open Sci 2023;50:43-6.
    Ghoreifi A; Djaladat H
    Eur Urol; 2023 Aug; 84(2):e53-e54. PubMed ID: 37149463
    [No Abstract]   [Full Text] [Related]  

  • 18. Reply to Shun Wan, Kun-peng Li, and Li Yang's Letter to the Editor re: Jordan M. Rich, Kennedy E. Okhawere, Charles Nguyen, et al. Transperitoneal Versus Retroperitoneal Single-port Robotic-assisted Partial Nephrectomy: An Analysis from the Single Port Advanced Research Consortium. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2023.06.004.
    Rich JM; Okhawere KE; Razdan S; Badani KK
    Eur Urol Focus; 2024 May; 10(3):495-496. PubMed ID: 37739915
    [No Abstract]   [Full Text] [Related]  

  • 19. Reply to Michael Staehler, Dena Battle, Axel Bex, Hans Hammers, and Daniel George's Letter to the Editor re: Arnaud Méjean, Alain Ravaud, Simon Thezenas, et al. Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma. Eur Urol 2018;74:842-3: Lymphocyte Phenotype and Timing of Radical Nephrectomy in Patients Treated with Immunocheckpoint Inhibitors for Renal Cell Carcinoma.
    Santoni M; Montironi R; Battelli N; Massari F
    Eur Urol; 2019 Mar; 75(3):e64-e66. PubMed ID: 30391082
    [No Abstract]   [Full Text] [Related]  

  • 20. Re: Julia Dagnæs-Hansen, Gitte Hjartbro Kristensen, Hein V. Stroomberg, Søren Schwartz Sørensen, Martin Andreas Røder. Surgical Approaches and Outcomes in Living Donor Nephrectomy: A Systematic Review and Meta-analysis. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2022.03.021.
    Pecoraro A; Li Marzi V; Serni S; Campi R
    Eur Urol Focus; 2023 Jan; 9(1):216-217. PubMed ID: 35798648
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.